Transcatheter Mitral Valve Replacement: An Update on Current Techniques, Technologies, and Future Directions.

Growing clinical data support the use of transcatheter therapies for significant mitral valve disease. Currently, edge-to-edge repair is the transcatheter treatment of choice, but many anatomies are not suitable. Transcatheter mitral valve replacement offers several potential advantages over transcatheter repair, most notably a greater and more sustained reduction in mitral regurgitation post-implantation, but also potential disadvantages. To enable the successful treatment of mitral valve disease in a wide range of patients and anatomies, we require an armory of transcatheter devices, including transcatheter mitral valve replacement systems.
Competing Interests: Funding Support and Author Disclosures Dr. Sathananthan is a consultant to Edward Lifesciences and Medtronic. Dr. Ye is a consultant to Edwards Lifesciences. Dr. Cheung is a consultant to Abbott Vascular, Medtronic, and Neovasc. Dr. Webb is a consultant to Edwards Lifesciences, Abbott Vascular, and Boston Scientific. Dr. Blanke is a consultant to Edwards Lifesciences, Tendyne, Neovasc, Circle Cardiovascular Imaging, and Gore. Dr. Leipsic is a consultant to Edwards Lifesciences, Neovasc, Abbott, Medtronic, and GE Healthcare; and has been a consultant to and holds stock in Circle Cardiovascular Imaging and HeartFlow. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.)